Video Experimental Relacionado
Updated: Jul 7, 2026
01:30
Development of Antibiotic Resistance
Published on: June 12, 2025
1.2K
El irbesartán, pero no la amlodipina, suprime la aterosclerosis asociada con la diabetes
Riccardo Candido1, Terri J Allen, Markus Lassila
1Vascular Division, Baker Heart Research Institute, PO Box 6492, Melbourne 8008, Victoria, Australia.
Circulation
|March 17, 2004
Resumen
El bloqueo del receptor de angiotensina II subtipo 1 con irbesartán, pero no con amlodipino, redujo la aterosclerosis en ratones diabéticos. Esto sugiere que el sistema renina-angiotensina juega un papel clave en la enfermedad vascular acelerada por la diabetes.
Área de la Ciencia:
- Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular Investigación cardiovascular
- Farmacología Farmacología.
- La diabetes mellitus es el tipo de diabetes.
Sus antecedentes:
- El papel del bloqueo del sistema renina-angiotensina (RAS) en la mitigación de la aterosclerosis en pacientes diabéticos sigue siendo objeto de debate.
- Comparar los bloqueadores RAS con otros antihipertensivos es crucial para comprender la protección cardiovascular en la diabetes.
Objetivo del estudio:
- Para comparar los efectos antiateroscleróticos de irbesartán (un bloqueador de los receptores AT1) y amlodipina (un antagonista de los canales de calcio) en un modelo de ratón de diabetes.
- Investigar los mecanismos moleculares subyacentes a la protección vascular en la aterosclerosis inducida por la diabetes.
Principales métodos:
- Los ratones de Apolipoproteína E-nulo fueron convertidos en diabéticos mediante el uso de estreptozotocina.
- Los ratones diabéticos no recibieron tratamiento, irbesartán o amlodipina durante 20 semanas.
- Se evaluó la formación de placa aórtica, la expresión de los receptores, la infiltración celular y los marcadores inflamatorios.
Principales resultados:
- La diabetes aumentó el área de la placa aórtica, la complejidad y la expresión del receptor AT1, PDGF-B, MCP-1 y VCAM-1.
- El irbesartán atenuó significativamente el desarrollo de la aterosclerosis y los cambios moleculares asociados.
- La amlodipina no mostró efectos antiateroscleróticos significativos a pesar de la reducción de la presión arterial comparable.
Conclusiones:
- El bloqueo del receptor AT1 mejora efectivamente la aterosclerosis asociada a la diabetes.
- El antagonismo de los canales de calcio no proporcionó una protección vascular similar.
- Estos hallazgos resaltan el papel crítico del RAS vascular en la progresión de la aterosclerosis inducida por la diabetes.
Videos de Conceptos Relacionados
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...